May 14, 2021
“GlycoMimetics (GLYC)… To this end, Jallah rates GLYC a Buy along with a $15 price target. Shares could appreciate by 567%, should the analyst’s thesis play out in the coming months… The company’s progress has attracted 3 unanimous positive reviews… Continue Reading…
January 21, 2021
“AzurRx BioPharma (AZRX)… Overall, the analyst consensus on AZRX shares is a Strong Buy; the stock has 4 recent reviews, including 3 Buys and a single Hold. In addition, the $4 average price target brings the upside potential to 304%…… Continue Reading…
October 13, 2020
“Outlook Therapeutics (OTLK)… Turning now to the rest of the Street, 3 Buys and no Holds or Sells have been published in the last three months. Therefore, OLTK has a Strong Buy consensus rating. With the average price target clocking… Continue Reading…
Recent Comments